Results 111 to 120 of about 34,375 (153)

AI-Driven Patient Screening for Clinical Trials in Pancreatic Cancer: The PANCR-AI Pilot Retrospective Comparative Study. [PDF]

JMIR Cancer
Claessens A, Simon A, Manchart A, Desmonts L, Leguay C, Faivre JC, Cambier S, Salleron J, Lambert A.   +8 more
europepmc   +1 more source

Comparative analysis of artificial intelligence-based contouring of cardiac substructures on computed tomography scans for radiation therapy. [PDF]

Phys Imaging Radiat Oncol
Moignier A, Perennec T, Prangères E, Bernard B, Botticella A, Chen X, Finnegan R, Huger S, Karlhede A, Lacornerie T, Löfman F, Palisson J, Robert C, Sambourg K, Söderberg J, Stoica R, Delpon G, Martin-Mervoyer E, Thillays F, Vaugier L.   +19 more
europepmc   +1 more source

Correction: Bourefis et al. HSP27/Menin Expression as New Prognostic Serum Biomarkers of Prostate Cancer Aggressiveness Independent of PSA. <i>Cancers</i> 2022, <i>14</i>, 4773. [PDF]

Cancers (Basel)
Bourefis A, Berredjem H, Djeffal O, Le TK, Giusiano S, Rocchi P.   +5 more
europepmc   +1 more source

Correction: Heat shock protein 27 phosphorylation state is associated with cancer progression. [PDF]

Front Genet
Katsogiannou M, Andrieu C, Rocchi P.
europepmc   +1 more source

Sensitive cell-free DNA assay for accurate detection of RAS and BRAF mutations in liquid biopsies of patients with metastatic colorectal cancer: Final results of the multicentric ColoBEAM study. [PDF]

Oncol Lett
Harlé A, Gavoille C, Bouché O, Abdelghani MB, Plaza J, Spaeth D, Boudrant A, Ghiringhelli F, Villing AL, Borg C, Rouyer M, Husson M, Gilson P, Salleron J, Lambert A, Merlin JL.   +15 more
europepmc   +1 more source

Correction: Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors. [PDF]

Front Oncol
Hargrave D, Marshall LV, André N, Krystal J, Ladle BH, Robbins KA, Hois S, Armstrong J, Donegan S.   +8 more
europepmc   +1 more source

Long-Term Response and Survival in Extensive-Stage SCLC Receiving Atezolizumab Plus Chemotherapy in a Real-World Setting: IFCT-1905 CLINATEZO. [PDF]

JTO Clin Res Rep
Falchero L, Amrane K, Godbert B, Leterre B, Madelaine J, Fournel P, Mascaux C, Raimbourg J, Schneider S, Swalduz A, Veillon R, Langlais A, Missy P, Morin F, Westeel V, Girard N.   +15 more
europepmc   +1 more source

BRCA1/2, PALB2 mutations and first-line CDK4/6 inhibitor efficacy in HR+ metastatic breast cancer. [PDF]

Breast
Guinel T, Lusque A, Mailliez A, Massard V, Jacot W, Guiu S, de la Motte Rouge T, Brain E, Desmoulins I, Arnedos M, Bailleux C, Goncalves A, Levy C, Bachelot T, Bosquet L, Delaloge S, Frénel JS.   +16 more
europepmc   +1 more source

Prospective pilot study with [⁸⁹Zr]Zr-girentuximab PET/CT: CA-IX imaging in metastatic triple negative breast cancer (OPALESCENCE). [PDF]

Eur J Nucl Med Mol Imaging
Rousseau C, Heyman MF, Ferrer L, Rauscher A, Morel A, Rusu D, Frenel JS, Taupin M, Vilcot L, Allam N, Robert M, Campone M, Campion L, Kraeber-Bodéré F.   +13 more
europepmc   +1 more source

14e Forum de Cancérologie Paris, 30 mai - 1er juin 1994

, 1994
Forum de Cancérologie 1994 Paris
core